These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37237267)

  • 1. Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy.
    Klehmet J; Tackenberg B; Haas J; Kieseier BC
    BMC Neurol; 2023 May; 23(1):207. PubMed ID: 37237267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Serbian version of inflammatory Rasch-built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Peric S; Bozovic I; Pruppers MHJ; Bjelica B; Stevic Z; Faber CG; Merkies ISJ; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):260-267. PubMed ID: 31397933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bjelica B; Peric S; Gwathmey K; Sadjadi R; Bozovic I; Burns TM; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):247-252. PubMed ID: 31209940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Brusse E; Jacobs BC; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Fokkink WR; Nieboer D; Lingsma HF; Merkies ISJ; van Doorn PA
    Eur J Neurol; 2021 Jan; 28(1):286-296. PubMed ID: 32876962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
    Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
    J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
    J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
    Hughes RA
    Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Kacar A; Peric S; Nikolic A; Bjelica B; Cobeljic M; Petrovic M; Stojanov A; Djuric V; Stojanovic M; Djordjevic G; Martic V; Dominovic A; Vukojevic Z; Basta I
    J Neurol; 2017 Dec; 264(12):2481-2486. PubMed ID: 29086018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home IVIG for CIDP: a focus on patient centred care.
    Katzberg HD; Rasutis V; Bril V
    Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.
    Anderson-Smits C; Ritchey ME; Huang Z; Chavan S; Souayah N; Ay H; Layton JB
    Neurol Ther; 2023 Aug; 12(4):1119-1132. PubMed ID: 37171778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: Results from the German INHIBIT registry.
    Mork H; Motte J; Fisse AL; Grüter T; Brünger J; Stoykova Z; Bulut Y; Athanasopoulos D; Sturm D; Tegenthoff M; Gold R; Enax-Krumova E; Pitarokoili K
    Eur J Neurol; 2022 Jul; 29(7):2109-2120. PubMed ID: 35357725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.